OHR Pharmaceutical, Inc., a clinical-stage pharmaceutical company, focuses on the development of novel therapies for the treatment of ophthalmic diseases. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine in combination with Lucentis injections, which completed Phase II clinical trials for the treatment of retinal diseases, including wet form of age-related macular degeneration, retinal vein occlusion, and diabetic retinopathy. It is also developing a sustained release ocular drug delivery platform technology. OHR Pharmaceutical, Inc. is headquartered in New York, New York.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OHRP
CUSIPN/A
Phone212-682-8452
Debt
Debt-to-Equity RatioN/A
Current Ratio3.37
Quick Ratio3.37
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.41 per share
Price / Book0.49
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-23,810,000.00
Net MarginsN/A
Return on Equity-72.65%
Return on Assets-61.31%
Miscellaneous
Employees4
Outstanding Shares56,470,000
Market Cap$11.74
OHR Pharmaceutical (NASDAQ:OHRP) Frequently Asked Questions
What is OHR Pharmaceutical's stock symbol?
OHR Pharmaceutical trades on the NASDAQ under the ticker symbol "OHRP."
How were OHR Pharmaceutical's earnings last quarter?
OHR Pharmaceutical Inc (NASDAQ:OHRP) issued its earnings results on Tuesday, May, 15th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.07) by $0.02. View OHR Pharmaceutical's Earnings History.
When is OHR Pharmaceutical's next earnings date?
What price target have analysts set for OHRP?
2 brokerages have issued twelve-month price objectives for OHR Pharmaceutical's stock. Their predictions range from $7.00 to $10.00. On average, they expect OHR Pharmaceutical's share price to reach $8.50 in the next twelve months. This suggests a possible upside of 4,150.0% from the stock's current price. View Analyst Ratings for OHR Pharmaceutical.
What is the consensus analysts' recommendation for OHR Pharmaceutical?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OHR Pharmaceutical in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
Who are some of OHR Pharmaceutical's key competitors?
Some companies that are related to OHR Pharmaceutical include Humanigen (HGEN), Moleculin Biotech (MBRX), AzurRx BioPharma (AZRX), Evoke Pharma (EVOK), Acerus Pharmaceuticals (TRLPF), Capricor Therapeutics (CAPR), Avenue Therapeutics (ATXI), Xenetic Biosciences (XBIO), Q BioMed (QBIO), Chiasma (CHMA), Nemus Bioscience (NMUS), Onconova Therapeutics (ONTX), PLx Pharma (PLXP), ProPhase Labs (PRPH) and BENITEC BIOPHAR/S (BNTC).
Who are OHR Pharmaceutical's key executives?
OHR Pharmaceutical's management team includes the folowing people:
- Dr. Jason Scott Slakter, CEO, Pres & Director (Age 60)
- Mr. Samuel Backenroth, Chief Financial Officer and VP of Bus. Devel. (Age 34)
- Dr. Glenn L. Stoller M.D., Chief Scientific Officer (Age 54)
- Dr. Peter K. Kaiser M.D., Head of Product Devel.
- Dr. Marlene Modi, Head of Preclinical & Regulatory Affairs
Has OHR Pharmaceutical been receiving favorable news coverage?
News headlines about OHRP stock have trended somewhat positive this week, Accern reports. The research group scores the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. OHR Pharmaceutical earned a media sentiment score of 0.18 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 44.78 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
How do I buy shares of OHR Pharmaceutical?
Shares of OHRP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OHR Pharmaceutical's stock price today?
One share of OHRP stock can currently be purchased for approximately $0.20.
How big of a company is OHR Pharmaceutical?
OHR Pharmaceutical has a market capitalization of $11.74 million. OHR Pharmaceutical employs 4 workers across the globe.
How can I contact OHR Pharmaceutical?
OHR Pharmaceutical's mailing address is 800 THIRD AVENUE 11TH FLOOR, NEW YORK NY, 10022. The biotechnology company can be reached via phone at 212-682-8452 or via email at [email protected]
MarketBeat Community Rating for OHR Pharmaceutical (NASDAQ OHRP)
MarketBeat's community ratings are surveys of what our community members think about OHR Pharmaceutical and other stocks. Vote "Outperform" if you believe OHRP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OHRP will underperform the S&P 500 over the long term. You may vote once every thirty days.
